April 23, 2024
ROME (Reuters) – Italy’s Senate gave final approval on Tuesday to a contested government plan to allow groups who “support motherhood” into abortion clinics to try […]
April 23, 2024
Summary Company Announcement Date: April 23, 2024 FDA Publish Date: April 23, 2024 Product Type: Drugs Reason for Announcement: Recall Reason Description Decreased Potency Company Name: […]
April 23, 2024
On April 23, 2024, the Food and Drug Administration approved lutetium Lu 177 dotatate (Lutathera, Advanced Accelerator Applications USA, Inc., a Novartis company) for pediatric patients […]
April 23, 2024
A | B | C | D | E | F | G | H | I | J | K | L | M | […]
April 23, 2024
Summary Company Announcement Date: April 22, 2024 FDA Publish Date: April 23, 2024 Product Type: Drugs Reason for Announcement: Recall Reason Description Product is tainted with […]
April 23, 2024
OSIS Workshop: CDER Inspections of Good Laboratory Practice and Bioavailability/Bioequivalence Study Sites Webinar 6/13/2024 Animal Rule, Bioanalysis, Bioavailability, Bioequivalence, Clinical Trials and Research, Good Laboratory Practice […]
April 23, 2024
The first-in-class complement factor D inhibitor danicopan (Voydeya) has been approved by the European Commission as an add-on agent for certain patients with the rare disease […]
April 23, 2024
Researchers have reviewed the evidence related to hyperemesis gravidarum and provided guidance for the diagnosis and treatment of this condition. Hyperemesis gravidarum, or severe nausea and […]
April 23, 2024
BOSTON — Behavioral avoidance could limit the long-term efficacy of exposure and response prevention (ERP), a widely used treatment for obsessive compulsive disorder (OCD), a new […]